Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy. 

Accept / Decline

Newsroom

Ferring Inc. Receives Health Canada Approval for REBYOTA® (fecal microbiota, live)

Toronto, ON – 6 March, 2025 – Ferring Inc. today announced that Health Canada has issued a Notice of Compliance, approving REBYOTA® (fecal microbiota, live), a novel first-in-class microbiome-restoration therapy indicated for the prevention of recurrence of Clostridioides difficile infection (C. diff) in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff. A Novel First-in-Class Microbiome-Restoration Therapy for the Prevention of Recurrence of C. diff Infection

A Novel First-in-Class Microbiome-Restoration Therapy for the Prevention of Recurrence of C. diff Infection

Click here to read the Press Release (English)

Cliquez ici pour lire le communiqué de presse (français)

See more Newsroom

Canada

Ferring Canada
200 Yorkland Boulevard, Suite 500
Toronto, Ontario, M2J 5C1 
Canada

Tel:  +1 416 490 0121 or +1 800 263 4057
Fax: 416 493 1692

Contact